Ampibactam (Sultamicillin) is a medication used to manage infections caused by susceptible bacteria, in conditions involving inflammatory or irritative processes. Its therapeutic scope is relevant across several key domains where symptoms relate to systemic imbalance and localized discomfort.

It is commonly used across conditions presenting with acute episodes, covering respiratory tract infections (like bacterial pneumonia and bronchitis), skin and soft tissue infections (such as cellulitis and abscesses), and complex internal infections (including pyelonephritis, otitis media, and gynecological infections). The medicine is applied across domains where additional symptomatic support is needed.

“This therapy is commonly used in settings where short-term symptomatic assistance is needed and helps maintain a sense of stability when symptoms are more noticeable.”

This medication is applied in clinical settings that involve acute or unstable symptom patterns, assisting with managing symptoms related to systemic imbalance and localized inflammation. This supports the patient by addressing symptoms like pain, fever, and swelling, contributing to improved day-to-day comfort and stability during the infectious phase.

---

Quick Fact: Support for Inflammatory States It is relevant for managing symptoms that create noticeable physiological strain, associated with inflammatory or irritative states.

Eligibility Map: Who can and cannot use Ampibactam — Official Regulatory Information

Eligibility scope

• Populations for whom use is allowed (as stated in label): Adult patients with susceptible bacterial infections; older children for whom safety and efficacy has been established.
• Populations for whom use is not recommended (if applicable): Pregnant individuals, unless the potential benefits are officially documented to outweigh the potential risk; individuals who are breastfeeding/lactating.
• Populations for whom use is contraindicated: Patients with a history of known hypersensitivity or allergic reaction to any penicillin or cephalosporin antibiotic; patients with infectious mononucleosis (glandular fever).

Age-related eligibility rules:

• Neonates and infants: Use requires caution, particularly due to renal function that is not fully developed, which affects drug clearance.
• Older adults (Geriatric patients): Use is generally acceptable, but caution is advised in dose selection due to the greater frequency of decreased renal function.

Condition-specific eligibility rules:

• Severe renal impairment (Creatinine clearance le 30 mL/min): Requires the dosage interval to be increased to prevent accumulation of the active components.
• Hepatic dysfunction/impairment: Requires monitoring of liver function at regular intervals.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Safety is not established; use is restricted to cases where potential benefit outweighs documented risk.
• Lactation: Use is not recommended, as low concentrations of the components are excreted in breast milk.

---

Eligibility classifications (high-level)

• Eligibility severity classification (as defined in official documents): Contraindicated; Not Recommended; Use with Caution.
• Regulatory basis: FDA Prescribing Information; European SmPC Section 4.3.

Official eligibility statements:

• Contraindicated in patients with a history of penicillin or cephalosporin allergy.
• Contraindicated in patients with infectious mononucleosis.
• Use in severe renal impairment requires dose interval adjustment.
• Use in pregnancy is only recommended when potential benefit outweighs risk.

Connection to the overall eligibility profile (Summary): Official regulatory documents define who can and cannot use Ampibactam by establishing a framework of absolute prohibitions based on allergy status and infectious diseases, while setting strict conditions for use in populations with organ impairment or specific physiological states such as pregnancy. These criteria serve as the mandated, label-based constraints that must be observed to determine population eligibility.

Documented Interactions with Medicines and Products

The official interaction profile for Ampibactam (Sultamicillin, a prodrug of Ampicillin and Sulbactam) primarily details restrictions related to altered drug concentrations and compromised therapeutic effects of co-administered agents.

Category	Documented Interaction Statement
Pharmacokinetic Interactions	Probenecid decreases the renal tubular secretion of Ampicillin and Sulbactam, resulting in increased and prolonged serum concentrations of the active components.
Methotrexate clearance is decreased when co-administered with penicillins, leading to an increase in methotrexate systemic exposure and toxicity risk.
Pharmacodynamic Interference	Live Bacterial Vaccines (e.g., Oral Cholera Vaccine) are documented as potentially having a decreased therapeutic effect due to antagonism. Bacteriostatic drugs (e.g., Tetracyclines) may interfere with Ampicillin’s bactericidal effect.
Increased Adverse Effects	Co-administration with Allopurinol substantially increases the documented incidence of skin rashes.
Timing and Efficacy	Estrogen-containing oral contraceptives have a documented risk of reduced effectiveness. The oral formulation's absorption may be reduced by food, necessitating separation from meals.

The regulatory profile establishes that co-administration with Probenecid is associated with heightened exposure to Ampibactam's active ingredients. The profile also highlights that co-use with certain agents, such as Methotrexate or live vaccines, leads to documented restrictions due to the risk of exposure modification or antagonism, respectively.

Ampibactam's action is achieved through the synergistic engagement of two distinct mechanistic domains that target bacterial cell wall synthesis and counteract beta-lactamase-mediated resistance.

---

beta-Lactamase Inhibition

This domain involves beta-lactamase inhibition, the mechanism by which the sulbactam component functions. Sulbactam acts as a suicide inhibitor, binding irreversibly to and inactivating bacterial beta-lactamase enzymes. This action modulates bacterial enzyme activity, permitting the unimpeded function of the beta-lactam component against its target.

---

Impairment of Bacterial Cell Wall Synthesis

The primary antibacterial domain is driven by ampicillin, which interferes with the final stages of peptidoglycan synthesis. Ampicillin binds to and inactivates bacterial penicillin-binding proteins (PBPs), halting the cross-linking necessary for cell wall formation. This disruption leads to an unstable cell wall and subsequent bacterial lysis.

---

Synergistic Action

The combination of these two distinct, yet complementary, mechanisms results in a synergistic effect. Sulbactam's mechanism allows ampicillin to engage its target, thereby extending the range of bacteria susceptible to the antibacterial response.

Administration Routes and Dosage

Ampibactam is supplied and administered through two primary methods. The active ingredient, Sultamicillin, is used for oral intake as either tablets or a suspension. The combination of Ampicillin and Sulbactam is administered parenterally via intravenous (IV) or intramuscular (IM) injection, utilizing the reconstituted powder form.

For adults, the typical oral dose of Sultamicillin is 375 mg to 750 mg taken twice daily (BID). The injectable Ampicillin/Sulbactam combination is usually administered at a total dose of 1.5 g to 3 g every six hours (q6h). The total daily dosage of the Sulbactam component must not exceed 4 grams.

---

Administration Conditions and Duration

Treatment duration is generally prescribed for 5 to 14 days, with a clinical requirement for a minimum of 10 days when addressing infections caused by beta-hemolytic streptococci. Oral Sultamicillin can be taken with or without food as this does not affect systemic absorption. To avoid possible irritation, the tablets must be ingested in an upright position with adequate fluid.

Parenteral IV administration must be performed slowly, either as an injection over at least 3 to 15 minutes or by infusion over 15 to 30 minutes. The reconstituted solution for IM use must be administered via deep intramuscular injection.

---

Population-Specific Dosing

Dosage interval adjustments are mandated for patients with severe renal impairment to account for the drug's excretion profile. For pediatric patients weighing less than 30 kg, oral dosing is weight-based, typically 25 to 50 mg/kg/day in two divided doses. Dosing for older adults is generally consistent with the standard adult regimen.

Research evidence / Overview of studies for Ampibactam

The research base for Ampibactam (Sultamicillin) was evaluated in research contexts in short-term treatment scenarios for common bacterial infections. The evidence primarily consists of Randomized Controlled Trials (RCTs) and comparative studies, which monitored outcomes related to systemic or functional imbalance over defined time intervals. These studies contribute to the broader evidence landscape by helping to show what has been observed so far. This structure is consistent with the evidence reviewed by authoritative regulatory bodies.

---

Evidence for Use in Skin and Soft Tissue Infections

Researchers utilized RCTs and comparative studies against established alternative antibiotics, applying them in studies examining patient-reported experiences for conditions like cellulitis and abscesses. These trials monitored specific outcomes related to clinical resolution of infection signs and success in eradicating the targeted bacteria. Findings describe patterns observed in the studies where clinical and bacteriological measurements were compared to those of established therapies.

Key limitations noted include that sample sizes were modest in some comparative trials. Furthermore, long-term effects are not well characterized regarding the durability of the response, as follow-up durations were limited to the immediate post-treatment period.

Evidence for Use in Respiratory Tract Infections

Clinical trials, including RCTs, were conducted during periods of increased symptom activity in both adults and children. Research examined the therapeutic response (categorized as cure or clinical improvement) and monitored outcomes related to symptom evolution. Studies monitored these responses over defined time intervals, reporting data that show patterns related to therapeutic response measured both immediately after the 10-day treatment course and again at 30 days later.

What remains uncertain is that there is limited information for long-term outcomes that track stability or recurrence patterns beyond the 30-day assessment in the primary trials.

What is Still Uncertain about Ampibactam Research

Key limitations noted in the regulatory record and peer-reviewed literature include: sample sizes were modest in some trials; follow-up durations were limited across the overall evidence base; and comparative evidence is lacking for some of the complex internal uses, which often rely on correlating the drug's properties with the known effects of the intravenous combination.

Key Studies & References

1. NIH National Library of Medicine: Drug Information (Combination Penicillins Class)
2. Efficacy and safety of Sultamicillin and Amoxicillin/Clavulanic Acid in the treatment of upper respiratory tract infections in adults
3. PILA trial: Levofloxacin vs piperacillin/sulbactam and sultamicillin in patients with acute cholecystitis (ISRCTN Registry)

Common questions about Ampibactam (FAQ)

---

Q: Is Ampibactam a 'broad-spectrum' medicine, or is it only for specific types of bacteria?

Regulatory documents classify Ampibactam as a penicillin antibiotic combined with a beta-lactamase inhibitor. The drug is indicated for specific infections caused by susceptible bacteria. These approved uses include infections in the skin and skin structure, intra-abdominal infections, and gynecological infections.

---

Q: Why is the term 'bactam' used in the drug name?

The drug contains two components, one of which is sulbactam, a beta-lactamase inhibitor. This component’s role is to chemically protect the ampicillin part of the medicine from being broken down by certain bacterial enzymes, thereby extending the antibacterial response.

---

Q: What are the key conditions that Ampibactam is formally indicated to treat?

According to official prescribing information, this combination drug is formally approved to treat infections caused by susceptible bacteria. These key conditions typically involve skin and skin structure infections, intra-abdominal infections, and infections within the female reproductive system.

---

Q: What kind of bacteria is Ampibactam specifically designed to target?

Ampibactam is used to target infections caused by bacteria that are resistant to certain single-agent antibiotics. It targets beta-lactamase-producing strains of specific organisms, which allows the ampicillin component to engage its antibacterial target.

---

Q: Is Ampibactam available as a generic version, or is it brand-only?

The active components of Ampibactam (ampicillin and sulbactam) are available in generic formulations from multiple manufacturers. This is in addition to the original brand name product, according to regulatory drug availability information.

---

Q: What are the most commonly reported side effects associated with Ampibactam?

Official information lists several commonly reported side effects. These typically include gastrointestinal issues such as diarrhea, nausea, and vomiting. For the injectable formulation, pain, redness, or irritation at the injection site is also commonly reported.

---

Q: Is feeling unusually tired a possible side effect of Ampibactam?

Official patient information describes a 'general feeling of tiredness or weakness' with this drug. However, the exact frequency of this specific side effect is not always known or listed as common.

---

Q: What are the known signs of a serious allergic reaction to Ampibactam?

Regulatory warnings state that serious, life-threatening allergic reactions, including anaphylaxis, can occur. Known signs can involve hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.

---

Q: Is an upset stomach a normal expectation when taking a course of Ampibactam?

Gastrointestinal symptoms such as nausea, vomiting, and diarrhea are reported as common side effects associated with the drug. Experiencing an upset stomach is a known possibility while taking the medication.

---

Q: Can taking Ampibactam cause a rash that is not an allergy?

Rash is officially listed as a common side effect of the drug. Additionally, the drug label also warns about the potential for serious skin reactions (like Stevens-Johnson syndrome) that are distinct from a typical allergic response.

---

Q: What steps do medical professionals take to monitor for potential liver issues while on Ampibactam?

Because liver problems have been reported with this drug, regulatory warnings indicate that medical professionals may monitor patients closely. This monitoring often involves conducting frequent blood tests to check liver function.

---

Q: Does Ampibactam carry any specific safety warnings listed by regulatory bodies?

Specific warnings listed by regulatory bodies include the risk of serious hypersensitivity reactions, potential liver toxicity (hepatotoxicity), and the possibility of Clostridium difficile-associated diarrhea (CDAD).

---

Q: What foods or supplements are officially documented to interact with Ampibactam?

Official product information states that consuming food may reduce the absorption of the ampicillin component. Core regulatory summaries typically do not list major interactions with specific vitamins or common herbal supplements.

---

Q: Is it necessary to avoid alcohol while taking Ampibactam?

No official regulatory warning explicitly prohibits the use of alcohol. However, official patient information describes that alcohol may potentially worsen common drug side effects such as stomach upset or dizziness, and this potential consequence is described in official patient information.

---

Q: Are there general classes of over-the-counter pain relievers that might interact with Ampibactam?

Regulatory-based interaction data indicates that the ampicillin component can interact with certain pain relievers containing salicylates (such as aspirin). This interaction may lead to increased levels of ampicillin in the body.

---

Q: What information is available on using Ampibactam during pregnancy or while breastfeeding?

The drug is assigned US FDA Pregnancy Category B, meaning animal studies have shown no fetal risk, but adequate human studies are not conclusive. Official documents also confirm that small amounts of both active drug components are excreted into human milk.

---

Q: Is there a documented contraindication for patients with a known penicillin allergy?

The drug is contraindicated in patients who have a known history of a severe allergic reaction (hypersensitivity) to penicillin-class antibiotics or cephalosporin antibiotics.

---

Q: What medical conditions, besides infection, might make a person ineligible for Ampibactam?

Official documents list certain conditions that may contraindicate use. These include a history of severe allergic reactions to penicillin or cephalosporin drugs, a diagnosis of mononucleosis, and a history of specific liver problems related to taking this drug.

---

Q: What is the reason why patients are often advised to complete the full prescribed course of Ampibactam?

Official warnings state that the prescribed full duration of treatment is intended to reduce the risk of the bacteria developing drug resistance.

---

Q: Can taking Ampibactam contribute to future antibiotic resistance issues?

Regulatory warnings indicate that the drug should be used only to treat infections caused by susceptible bacteria. This approach is designed to help reduce the development of drug-resistant bacteria.

---

Q: What is the recommended way to store Ampibactam tablets or liquid suspension?

The sterile powder form (used for injection) is required to be stored at or below 30 C (86 F) before it is mixed. Storage requirements for the tablets and liquid suspensions are provided in the official patient information leaflet.

---

Q: What research evidence is available regarding the use of Ampibactam in older adult populations?

Pharmacokinetic data from studies on the drug indicate that the body's clearance of both the ampicillin and sulbactam components is typically slowed in older adult populations. This observation guides the dosing principles for this group.

---

Q: Why do some formulations of Ampibactam need to be mixed or reconstituted?

The injectable formulation of Ampibactam is supplied as a sterile powder. This sterile powder formulation is required to be reconstituted with a sterile diluent to create a solution ready for administration.

---

Q: Is it true that antibiotics like Ampibactam can sometimes cause a secondary infection?

Official warnings state that antibiotics can sometimes lead to secondary infections. These can include Clostridium difficile-associated diarrhea (CDAD) or fungal overgrowth, such as thrush (white patches in the mouth or throat).

---

Q: What makes the treatment regimen for Ampibactam specific to certain infections?

The specific regimen, including the dose amount, frequency, and overall duration of treatment, is defined in regulatory documents. This approach is specific because the requirements vary based on the type and severity of the infection being treated.

---

Q: Why is Ampibactam generally administered in a healthcare setting versus being taken entirely at home?

Ampibactam is manufactured in both an oral formulation (typically taken at home) and an injectable (parenteral) formulation. The injectable form (IV or IM) is typically reserved for more severe infections and is administered by healthcare professionals in a clinical setting.

---

Q: Is Ampibactam the same as or similar to other drugs ending in '-cillin'?

Yes, Ampibactam is classified as a penicillin antibiotic combined with a beta-lactamase inhibitor. The ampicillin component is a core member of the penicillin ('-cillin') class of antibiotics.

The storage and disposal of Ampibactam (Sultamicillin) must adhere strictly to official regulatory guidelines, which vary by formulation.

Storage Conditions

The dry powder for injection must be stored at controlled room temperature, typically 20 C to 25 C. Oral forms must be stored below 30 C, protected from moisture, and kept in the original, tightly closed container. The reconstituted oral suspension requires refrigeration, 2 C to 8 C, and must be discarded after 14 days. Do not freeze any solutions or suspensions.

Handling and Disposal

All forms of Ampibactam must be kept out of the sight and reach of children. Unused or expired product should not be disposed of in household waste or wastewater. Instead, disposal must be conducted in accordance with local pharmaceutical waste requirements.